A multicenter, randomized, doubleblind, placebo-controlled trial of amantadine to stimulate awakening in comatose patients resuscitated from cardiac arrest
Clinical and Experimental Emergency Medicine · 29.01.2024 · 11 (2) · 205-212
DOI: 10.15441/ceem.23.158 ↗Kurz gefasst
Fachartikel in der Zeitschrift Clinical and Experimental Emergency Medicine, online erschienen am 29.01.2024. Verfasst von Patrick J Coppler und 13 weiteren Autor:innen. Beteiligte Einrichtung: Department of Emergency Medicine, University of Pittsburgh, Pittsburgh, PA, USA. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 27 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 3.0). Gefördert von: NIGMS NIH HHS.
Themen: Reanimation
Abstract (Originalsprache)
Objective
We hypothesized that the administration of amantadine would increase awakening of comatose patients resuscitated from cardiac arrest.
Methods
We performed a prospective, randomized, controlled pilot trial, randomizing subjects to amantadine 100 mg twice daily or placebo for up to 7 days. The study drug was administered between 72 and 120 hours after resuscitation and patients with absent N20 cortical responses, early cerebral edema, or ongoing malignant electroencephalography patterns were excluded. Our primary outcome was awakening, defined as following two-step commands, within 28 days of cardiac arrest. Secondary outcomes included length of stay, awakening, time to awakening, and neurologic outcome measured by Cerebral Performance Category at hospital discharge. We compared the proportion of subjects awakening and hospital survival using Fisher exact tests and time to awakening and hospital length of stay using Wilcoxon rank sum tests.
Results
After 2 years, we stopped the study due to slow enrollment and lapse of funding. We enrolled 14 subjects (12% of goal enrollment), seven in the amantadine group and seven in the placebo group. The proportion of patients who awakened within 28 days after cardiac arrest did not differ between amantadine (n=2, 28.6%) and placebo groups (n=3, 42.9%; P>0.99). There were no differences in secondary outcomes. Study medication was stopped in three subjects (21.4%). Adverse events included a recurrence of seizures (n=2; 14.3%), both of which occurred in the placebo group.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Emergency Medicine, University of Pittsburgh, Pittsburgh, PA, USA.
- Department of Critical Care Services, Maine Medical Center, Portland, ME, USA.
- Department of Critical Care Medicine, University of Pittsburgh, Pittsburgh, PA, USA.
- Department of Neurology, University of Pittsburgh, Pittsburgh, PA, USA.
- Department of Pediatrics, Baylor College of Medicine, Houston, TX, USA.
- Department of Medicine, Albert Einstein College of Medicine, New York, NY, USA.
Förderung
- NIGMS NIH HHS
Zitieren
APA
Coppler, P. J., Gagnon, D. J., Flickinger, K. L., Elmer, J., Callaway, C. W., Guyette, F. X., Doshi, A., Steinberg, A., Dezfulian, C., Moskowitz, A. L., Donnino, M., May, T. L., Seder, D. B., & Rittenberger, J. C. (2024). A multicenter, randomized, doubleblind, placebo-controlled trial of amantadine to stimulate awakening in comatose patients resuscitated from cardiac arrest. Clinical and Experimental Emergency Medicine, 11(2), 205-212. https://doi.org/10.15441/ceem.23.158
Vancouver
Coppler PJ, Gagnon DJ, Flickinger KL, Elmer J, Callaway CW, Guyette FX, et al. A multicenter, randomized, doubleblind, placebo-controlled trial of amantadine to stimulate awakening in comatose patients resuscitated from cardiac arrest. Clinical and Experimental Emergency Medicine. 2024;11(2):205-212. doi:10.15441/ceem.23.158
BibTeX
@article{Coppler2024,
author = {Coppler, Patrick J and Gagnon, David J and Flickinger, Katharyn L and Elmer, Jonathan and Callaway, Clifton W and Guyette, Francis X and Doshi, Ankur and Steinberg, Alexis and Dezfulian, Cameron and Moskowitz, Ari L and Donnino, Michael and May, Teresa L and Seder, David B and Rittenberger, Jon C},
title = {A multicenter, randomized, doubleblind, placebo-controlled trial of amantadine to stimulate awakening in comatose patients resuscitated from cardiac arrest},
journal = {Clinical and Experimental Emergency Medicine},
year = {2024},
volume = {11},
number = {2},
pages = {205--212},
doi = {10.15441/ceem.23.158}
}
EUVIMED